COVID-19: Cedars-Sinai physician co-authors analysis of antiviral drug

April 11, 2020

LOS ANGELES (April 11, 2020) -- In a small group of patients hospitalized with severe complications of COVID-19 and treated with the experimental antiviral drug remdesivir, clinical improvement was observed in 68% of patients treated, according to an analysis co-authored by Jonathan Grein, MD, director of Hospital Epidemiology at Cedars-Sinai.

The experimental therapy was given to patients through a "compassionate use" program that allows providers access to treatments not yet approved by the Food and Drug Administration when a patient has a life-threatening condition and no other options are available.

The analysis, published online today by The New England Journal of Medicine, evaluated data from 53 patients in the U.S, Europe, Canada and Japan who received at least one dose of remdesivir by March 7. The effort was led by Gilead Sciences, the pharmaceutical company that makes the experimental drug.

The study shows:"Currently there is no proven treatment for COVID-19. We cannot draw definitive conclusions from these data, but the observations from this group of hospitalized patients who received remdesivir are hopeful," said Grein, who also leads the Special Pathogens Response Team at Cedars-Sinai. "We look forward to the results of controlled clinical trials to potentially validate these findings."

Cedars-Sinai is continuing to explore remdesivir as a therapeutic option for patients as part of a large international randomized controlled study sponsored by the NIH.

Compassionate use programs are less stringent than a randomized controlled study, which compares patients who are receiving the experimental treatment to patients receiving the standard treatment. However, during the COVID-19 pandemic, compassionate use data can help scientists understand potential risks and can offer a glimpse into whether an experimental treatment might or might not be viable.

"It's critical that the medical community finds a safe and effective treatment for COVID-19 that's supported by solid data," Grein said. "I'm very proud that Cedars-Sinai is contributing to the global effort to find that solution."
Funding: Research reported in this publication was supported by Gilead Sciences.

Cedars-Sinai Medical Center

Related Data Articles from Brightsurf:

Keep the data coming
A continuous data supply ensures data-intensive simulations can run at maximum speed.

Astronomers are bulging with data
For the first time, over 250 million stars in our galaxy's bulge have been surveyed in near-ultraviolet, optical, and near-infrared light, opening the door for astronomers to reexamine key questions about the Milky Way's formation and history.

Novel method for measuring spatial dependencies turns less data into more data
Researcher makes 'little data' act big through, the application of mathematical techniques normally used for time-series, to spatial processes.

Ups and downs in COVID-19 data may be caused by data reporting practices
As data accumulates on COVID-19 cases and deaths, researchers have observed patterns of peaks and valleys that repeat on a near-weekly basis.

Data centers use less energy than you think
Using the most detailed model to date of global data center energy use, researchers found that massive efficiency gains by data centers have kept energy use roughly flat over the past decade.

Storing data in music
Researchers at ETH Zurich have developed a technique for embedding data in music and transmitting it to a smartphone.

Life data economics: calling for new models to assess the value of human data
After the collapse of the blockchain bubble a number of research organisations are developing platforms to enable individual ownership of life data and establish the data valuation and pricing models.

Geoscience data group urges all scientific disciplines to make data open and accessible
Institutions, science funders, data repositories, publishers, researchers and scientific societies from all scientific disciplines must work together to ensure all scientific data are easy to find, access and use, according to a new commentary in Nature by members of the Enabling FAIR Data Steering Committee.

Democratizing data science
MIT researchers are hoping to advance the democratization of data science with a new tool for nonstatisticians that automatically generates models for analyzing raw data.

Getting the most out of atmospheric data analysis
An international team including researchers from Kanazawa University used a new approach to analyze an atmospheric data set spanning 18 years for the investigation of new-particle formation.

Read More: Data News and Data Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to